Salix takes center stage in drug-stock trading
February 24, 2011 at 11:15 AM EST
Shares of Salix are plunging on news that the FDA does not plan to approve its drug Xifaxan at this time.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.